HeartFlow Public Company (NYSE:HFLO)

Primary contact

🚀 Merged with Longview Acquisition Corp. II on July 15, 2021. in a SPAC deal worth $2.4B, raising $400M in the process.
HeartFlow is on a mission to revolutionize precision heart care, with its non-invasive HeartFlow FFRCT Analysis leveraging AI to create a personalized 3D model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. As such, the HeartFlow FFRct Analysis is well positioned to become an integral part of the standard of care for patients who are at risk for coronary artery disease (CAD) because of its potential to improve both clinical outcomes and the patient experience while reducing the cost of care.
Primary contact

Funding 💰

Total $543M
Select investors Capricorn Investment Group, Panorama Point Partners, US Venture Partners, Baillie Gifford, Wellington Management, BlueCross BlueShield Venture Partners
Last update: September 4, 2021